Peter Marks Biography and Net Worth

Director of Alterity Therapeutics

Mr Marks has served as a director of Alterity since July 2005. He is an experienced company director with significant corporate advisory and investment experience. In his roles with these various financial institutions, Mr. Marks was responsible for advising a substantial number of listed and unlisted companies on issues ranging from corporate and company structure, to valuation, business strategies, acquisitions and international opportunities.

For over 13 years until the end of August 2014, Mr. Marks was a Director of investment bank Peregrine Corporate Ltd, and is currently Chairman of Newburyport Partners, a boutique corporate and capital markets advisory firm specializing in advising small to mid-cap companies.

Mr Marks is currently a non-executive Director of Electriq Global Ltd, and also currently serves as Director of Noxopharm Ltd, an ASX listed biotechnology company, and Noxopharm subsidiary, Nyrada Inc.

What is Peter Ashley Marks' net worth?: The estimated net worth of Peter Ashley Marks is at least $743.55 thousand as of August 31st, 2026. Marks owns 191,340 shares of Alterity Therapeutics stock worth more than $743,547 as of September 18th. This net worth evaluation does not reflect any other investments that Marks may own. Learn More about Peter Ashley Marks' net worth.
How do I contact Peter Ashley Marks?: The corporate mailing address for Marks and other Alterity Therapeutics executives is LEVEL 3 460 BOURKE STREET, MELBOURNE C3, VIC 3000. Alterity Therapeutics can also be reached via phone at (139) 349-4906 and via email at [email protected]. Learn More on Peter Ashley Marks' contact information.
Has Peter Ashley Marks been buying or selling shares of Alterity Therapeutics?: Over the course of the past ninety days, Peter Ashley Marks has bought $23,810.00 in Alterity Therapeutics stock. Most recently, on Monday, August 31st, Peter Ashley Marks bought 47,620 shares of Alterity Therapeutics stock. The stock was acquired at an average cost of $0.50 per share, with a total value of $23,810.00. Following the completion of the transaction, the director now directly owns 191,340 shares of the company's stock, valued at $95,670. Learn More on Peter Ashley Marks' trading history.
Are insiders buying or selling shares of Alterity Therapeutics?: During the last year, Alterity Therapeutics insiders bought shares 1 times. They purchased a total of 47,620 shares worth more than $23,810.00. The most recent insider tranaction occured on August, 31st when Director Peter Ashley Marks bought 47,620 shares worth more than $23,810.00. Insiders at Alterity Therapeutics own 38.8% of the company. Learn More about insider trades at Alterity Therapeutics.
Information on this page was last updated on 8/31/2026.

Peter Ashley Marks Insider Trading History at Alterity Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/31/2026	Buy	47,620	$0.50	$23,810.00	191,340

Peter Ashley Marks Buying and Selling Activity at Alterity Therapeutics

Alterity Therapeutics Company Overview

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Today's Range

Now: $3.91

$3.80

$3.92

50 Day Range

MA: $4.57

$3.50

$5.43

2 Week Range

Now: $3.91

$2.66

$5.89

Volume

3,088 shs

Average Volume

26,449 shs

Market Capitalization

$70.87 million

P/E Ratio

N/A

Dividend Yield